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Abstract
Background: Epidemiologic studies of alcoholic hepatitis (AH) have been hindered by the lack of a validated
International Classification of Disease (ICD) coding algorithm for use with administrative data. Our objective was to
validate coding algorithms for AH using a hospitalization database.
Methods: The Hospital Discharge Abstract Database (DAD) was used to identify consecutive adults (≥18 years)
hospitalized in the Calgary region with a diagnosis code for AH (ICD-10, K70.1) between 01/2008 and 08/2012.
Medical records were reviewed to confirm the diagnosis of AH, defined as a history of heavy alcohol consumption,
elevated AST and/or ALT (<300 U/L), serum bilirubin >34 μmol/L, and elevated INR. Subgroup analyses were
performed according to the diagnosis field in which the code was recorded (primary vs. secondary) and AH
severity. Algorithms that incorporated ICD-10 codes for cirrhosis and its complications were also examined.
Results: Of 228 potential AH cases, 122 patients had confirmed AH, corresponding to a positive predictive
value (PPV) of 54 % (95 % CI 47–60 %). PPV improved when AH was the primary versus a secondary diagnosis
(67 % vs. 21 %; P < 0.001). Algorithms that included diagnosis codes for ascites (PPV 75 %; 95 % CI 63–86 %), cirrhosis
(PPV 60 %; 47–73 %), and gastrointestinal hemorrhage (PPV 62 %; 51–73 %) had improved performance, however, the
prevalence of these diagnoses in confirmed AH cases was low (29–39 %).
Conclusions: In conclusion the low PPV of the diagnosis code for AH suggests that caution is necessary if this
hospitalization database is used in large-scale epidemiologic studies of this condition.
Background
Alcoholic hepatitis (AH) is a clinical syndrome charac-
terized by hepatic dysfunction in the setting of heavy
alcohol intake. Rapid onset of jaundice is a cardinal
manifestation of AH; other common signs include fever,
ascites, muscle wasting and hepatic encephalopathy [1].
AH is often complicated by infection and hepatorenal
syndrome, both of which significantly increase mortality
[2–4]. Untreated patients with severe AH, typically
defined by a Maddrey discriminant function (DF) ≥32
and/or the presence of hepatic encephalopathy, have a
particularly poor prognosis with one-month mortality
rates ranging from 30 % to 50 % [5, 6]. In patients with a
mild presentation of AH, the risk of progression to
cirrhosis is 50 %; this risk is highest in patients who
continue to abuse alcohol [7].
Population-based studies describing the epidemiology
and outcomes of AH are limited. A Danish study by
Sandahl et al. [8] was the first population-based epidemi-
ologic study of AH and demonstrated an increase in
annual incidence among both Danish men and women
between 1999 and 2008. Another study described the clin-
ical characteristics and mortality of patients hospitalized in
the United States for AH using the Nationwide Inpatient
Sample (NIS) database [9]. Both of these studies relied on
International Classification of Diseases (ICD) diagnosis
codes for AH in an administrative database for case identi-
fication. Although such codes have been validated for other
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non-hepatic and hepatic conditions (e.g. cirrhosis, viral
hepatitis, autoimmune liver disease, drug hepatotoxicity)
[10–21], their validity for AH has yet to be confirmed.
While the burden of alcohol-related liver disease is in-
creasing in many regions, large-scale studies describing
the epidemiology of AH in Canada have been hindered
by the lack of a validated coding algorithm. Therefore,
the primary objective of our study was to validate cod-
ing algorithms for the identification of patients hospi-
talized for AH using administrative data. Our study
findings will inform researchers if administrative data




In this retrospective study, the hospital Discharge
Abstract Database (DAD) was queried to identify adults
(age ≥18 years) hospitalized in the Calgary region in the
province of Alberta, Canada with a primary or secondary
diagnosis of AH (ICD-10 diagnosis code, K70.1 [22]) be-
tween January 2008 and August 2012. Only the first
hospitalization was considered among patients with mul-
tiple admissions for AH to avoid selection bias. Specific-
ally, patients diagnosed with AH are more likely to be
diagnosed with AH again during future admissions,
thereby falsely elevating coding validity. The Calgary re-
gion included three adult, acute care hospitals and served
a catchment population of approximately 1.5 million indi-
viduals. Over 99 % of Alberta residents are registrants of
the Alberta Health Care Insurance Plan, a universal
plan that covers all hospitalization costs [23]. The DAD
contains up to 25 diagnoses, 20 procedures, and mor-
tality information on all discharges from Calgary hospi-
tals. This database has been used to examine the
epidemiology [24, 25], outcomes [26–33], and coding
accuracy [18, 24] of various medical conditions. This
study protocol and a waiver of consent was approved
by the Conjoint Health Research Ethics Board at the
University of Calgary.
Data extraction and definition of AH
Admissions were randomly assigned to one of three phy-
sicians experienced in the care of patients with AH (MB,
ER, JP) who reviewed the paper and electronic medical
records for each individual to confirm the diagnosis of AH
during their index admission. Using a structured data col-
lection instrument, the following details were recorded:
age, sex, year and site of hospitalization, liver bio-
chemistry (serum alanine aminotransferase [ALT],
aspartate aminotransferase [AST], gamma-glutamyl-
transpeptidase [GGT], bilirubin, albumin concentrations,
and international normalized ratio [INR]) and serum
creatinine at admission, clinical evidence of hepatic
encephalopathy (based on the impression of the attending
physician) or ascites (detected clinically or radiologically),
and self-reported recent average daily alcohol intake. Since
alcohol intake varied throughout some medical records, a
hierarchical approach was taken. Specifically, data was first
taken from consultation notes by addictions specialists
where available, followed by the admission history, and
otherwise, from patient progress notes. The severity of
hepatic dysfunction was described using the Model for
End-Stage Liver Disease (MELD) score [34] and Maddrey
DF, validated prognostic scoring systems for patients with
AH. Patients with a Maddrey DF ≥32 and/or the presence
of hepatic encephalopathy were classified as severe [6].
Length of stay (LOS) and mortality (in-hospital and at 90
and 180 days) were also recorded.
Although the reference standard for the diagnosis of
AH includes liver biopsy, this procedure is not part of
the routine clinical management of patients with sus-
pected AH in Calgary hospitals. Therefore, patients were
considered to have a confirmed diagnosis of AH if they
fulfilled all the following criteria based on history and la-
boratory investigations at hospital admission: 1) heavy
alcohol consumption (>196 g/week or >56 g in any day
among males, and >98 g/week or >42 g in any day
among females) [35]; 2) elevated serum AST and/or ALT
concentration, but <300 IU/L (to exclude other disorders
associated with acute hepatic dysfunction including
acetaminophen toxicity); 3) serum bilirubin >34 μmol/L;
4) elevated INR; and 5) exclusion of other causes of
acute hepatic dysfunction (e.g. drug hepatotoxicity, auto-
immune hepatitis, ischemic hepatitis, etc.). Patient with
missing information on any of the above criteria are
considered “Not AH”. To confirm the inter-rater agree-
ment of a diagnosis of AH according to these criteria, 21
patients were randomly selected and all three physicians
reviewed their medical records. In cases of disagreement,
a consensus was reached.
Statistical analyses
Between groups comparisons were made using Fisher's
exact and χ2 tests for categorical variables, and Wilcoxon
rank-sum test for continuous variables. Using data from
medical records as the reference standard for the diag-
nosis of AH, we calculated the positive predictive value
(PPV) for each administrative data coding algorithm
with exact binomial 95 % confidence intervals (CI). Due
to the lack of an unaffected control group, we could not
calculate the sensitivity, specificity, or negative predictive
values of these algorithms. Subgroup analyses of algo-
rithm accuracy were performed according to the diagnosis
field in which the code for AH was recorded (primary vs.
secondary) and AH severity (mild vs. severe), with a severe
presentation defined by a Maddrey DF of ≥32 and/or the
presence of hepatic encephalopathy. Further stratification
Pang et al. BMC Gastroenterology  (2015) 15:116 Page 2 of 8
by fiscal year and admitting hospital was performed to as-
sess for any temporal changes in coding accuracy or het-
erogeneity between hospitals, which employ different
health records coders. In addition, the diagnostic accuracy
of algorithms that incorporated ICD-10 diagnosis codes for
cirrhosis and its complications (i.e. ascites, gastrointes-
tinal hemorrhage, hepatic encephalopathy, malnutri-
tion, hepatorenal syndrome/renal failure) and alcohol-
related disorders (i.e. alcohol abuse, alcohol dependence,
alcohol withdrawal, and pancreatitis) were examined
(see Appendix for codes). Algorithms that accounted for
the number of associated conditions were also assessed. Fi-
nally, inter-rater agreement for the diagnosis of AH, with
subgroup analyses according to disease severity, was calcu-
lated using the kappa statistic [36]. All analyses were per-
formed using Stata version 11.0 (StataCorp; College




A total of 228 patients were hospitalized in the Calgary
region between January 2008 and August 2012 with a
diagnosis code for AH (71 % [n = 161] as the primary
diagnosis). Their characteristics are outlined in Table 1.
The median age was 49 years (interquartile range [IQR]
43–55) and 61 % of the cohort was male. A similar
proportion was hospitalized at each of the three adult
hospitals in Calgary (P = 0.69). The majority of cases
(62 %, n = 142) had a severe presentation. Overall, median
length of stay was 7 days (IQR 5–15) and in-hospital mor-
tality was 6 % (n = 13). Compared with those with a mild
presentation, patients with a severe presentation had a pro-
longed median LOS (5 vs. 10 days; P < 0.001) and greater
in-hospital mortality (0 % vs. 9 %; P = 0.002).
Validation of an AH diagnosis based on administrative data
Of the 228 potential AH cases, 122 patients had
confirmed AH based on medical record review, corre-
sponding to a PPV of 54 % (95 % CI 47-60 %). Overall,
inter-rater agreement for an AH diagnosis was good
(kappa 0.86; P < 0.001), and higher among patients with
a severe (kappa 0.88; P < 0.001) versus mild (kappa 0.80;
P < 0.002) presentation. Compared to unconfirmed cases,
patients with confirmed AH had greater liver disease
severity according to the Maddrey DF (45 vs. 12; P < 0.001)
and MELD scores (21 vs. 13; P < 0.001); a higher preva-
lence of ascites (38 % vs. 14 %; P < 0.001); a lower preva-
lence of alcohol withdrawal (16 % vs. 26 %; P = 0.05); and
greater 90-day and 180-day mortality (Table 1). Patients
with confirmed AH also had greater median daily alcohol
intake (121 vs. 112 g; P = 0.024), however, there was no sig-
nificant difference in the proportion of patients that had
daily alcohol intake within the top quartile (24 % vs. 25 %;
P = 0.87). Differences between confirmed and unconfirmed
AH cases were not observed with respect to age, sex,
admitting hospital, year of admission, or the remaining
cirrhosis and alcohol-related complications (Table 1).
Subgroup analyses of AH coding algorithm validity
Among confirmed AH cases, 89 % (108/122) had an AH
code recorded as the primary diagnosis compared with
only 50 % (53/106) among unconfirmed cases (P < 0.001).
The PPV improved from 54 % overall to 67 % (95 % CI 59-
74 %) when AH was the primary diagnosis versus 21 %
(95 % CI 12-33 %) when AH was recorded as a secondary
diagnosis (P < 0.001). A severe presentation was also more
common in patients with confirmed AH versus uncon-
firmed cases (80 % [97/122] vs. 43 % [45/106]; P < 0.001).
Accordingly, the PPV of an AH diagnosis was higher
among severe compared to mild cases (68 % [95 % CI 60-
76 %] vs. 29 % [95 % CI 20-40 %]; P < 0.001). When strati-
fied by year of hospitalization, the PPV was highest in 2012
(70 %; 95 % CI 54-83 %) compared to 2008 through 2011
(45 % to 54 %), however, this difference was not statistically
significant (P = 0.17). Comparison of the PPV between ad-
mitting hospitals, which ranged from 50 % to 57 %, showed
no significant differences between centres (P = 0.69).
The PPVs of diagnostic algorithms that included codes
for cirrhosis and alcohol-related conditions in the ad-
ministrative data are shown in Table 2. The PPVs tended
to be higher for algorithms that included ascites (75 %;
95 % CI 63-86 %), gastrointestinal hemorrhage (62 %;
95 % CI 51-73 %), and cirrhosis (60 %; 95 % CI 47-
73 %). In general, these PPVs improved when restricted
to cases with an AH code in the primary diagnosis field
and those with severe presentations (Table 2). However,
the prevalence of these conditions in patients with con-
firmed AH was low, ranging from 29 % for cirrhosis to
39 % for gastrointestinal hemorrhage. The prevalence of
codes for other cirrhosis and alcohol-related disorders
were generally too low or their inclusion did not en-
hance the PPV of the algorithms (Table 2). For example,
a diagnosis code for hepatic encephalopathy was re-
corded in only 2.5 % of confirmed AH cases (4.2 % of se-
vere cases), and thus, the PPV of an algorithm including
both an AH and hepatic encephalopathy code was only
50 % (95 % CI 12-88 %). Stratification by year and hospital
of admission did not indicate any consistent differences
between PPVs for these algorithms (data not shown).
Table 3 outlines the performance characteristics of
algorithms according to the number of cirrhosis and
alcohol-related conditions recorded in the administrative
data in addition to an AH diagnosis code. In patients
with three or more associated conditions, the PPV for
confirmed AH improved to 62 % to 79 %; however, only
6 % to 34 % of confirmed cases had this number of add-
itional diagnoses in their administrative data.
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Discussion
In this population-based study, we assessed the validity
of ICD diagnosis coding algorithms for AH in a
Canadian hospitalization database. Our finding of a low
PPV for AH (54 %) suggests that AH was not accurately
and completely coded in the administrative data and
caution must be exercised if the DAD is used for large-
scale epidemiologic studies of AH. Under the assump-
tion that the PPV remains relatively constant over time
(as observed in our study), the DAD could be used to as-
sess temporal trends in AH admissions. However, the
exact incidence for any given year based on this data is
likely to be erroneous. Administrative data could also be
used as a screening tool for potential cases with AH. In
this situation, confirmation of the presence of AH
requires additional clinical information such as that
obtainable via a review of medical records. In light of
our findings, the validity of previous studies that used
Table 1 Characteristics of the study population
Entire cohort (n = 228) Confirmed AH cases (n = 122) Unconfirmed AH cases (n = 106) P-value
Age, years 49 (43–55) 49 (42–55) 49 (44–58) 0.33
Male 61 % (138) 60 % (73) 61 % (65) 0.89
Self-reported alcohol consumption, g/day 119 (81–224) 121 (84–233) 112 (56–208) 0.024
Excessive intake a 91 % (208) 100 % (122) 81 % (86) <0.001
Proportion in the highest intake quartile 25 % (50) 25 % (29) 24 % (21) 0.87
Admission hospital 0.69
1 39 % (90) 42 % (51) 37 % (39)
2 30 % (68) 29 % (36) 31 % (32)
3 31 % (70) 29 % (35) 33 % (35)
Year of admission 0.16
2008 25 % (56) 22 % (27) 27 % (29)
2009 17 % (40) 15 % (18) 21 % (22)
2010 18 % (41) 17 % (21) 19 % (20)
2011 21 % (48) 21 % (26) 21 % (22)
2012 19 % (43) 25 % (30) 12 % (13)
Biochemical status
Maddrey DF 29 (13–52) 45 (26–62) 12 (5–30) <0.001
MELD 18 (13–23) 21 (18–24) 13 (8–19) <0.001
Severe b 62 % (142) 80 % (97) 42 % (45) <0.001
Associated conditions
Cirrhosis 25 % (58) 29 % (35) 22 % (23) 0.29
Ascites 27 % (61) 38 % (46) 14 % (15) <0.001
GI hemorrhage 34 % (77) 39 % (48) 27 % (29) 0.07
Hepatic encephalopathy 2.6 % (6) 2.5 % (3) 2.8 % (3) 1
Malnutrition 3.0 % (7) 4.1 % (5) 1.9 % (2) 0.45
HRS/renal failure 16 % (36) 18 % (22) 13 %(14) 0.37
Pancreatitis 7.9 % (18) 4.9 % (6) 11 % (12) 0.09
Alcohol abuse 36 % (81) 38 % (46) 33 % (35) 0.49
Alcohol dependence 26 % (60) 28 % (34) 25 % (26) 0.65
Alcohol withdrawal 21 % (47) 16 % (19) 26 % (28) 0.05
Mortality
In-hospital 5.7 % (13) 7.4 % (9) 3.7 % (4) 0.27
90 days 13 % (29) 17 % (21) 8.5 % (9) 0.045
180 day 17 % (38) 23 % (28) 11 % (12) 0.007
Data are presented as median (IQR) or % (n). DF discriminant function, GI gastrointestinal, HRS hepatorenal syndrome; MELD, Model for End-Stage Liver Disease
a As defined in the Methods
b Severe presentation is characterized by a Maddrey DF of ≥32 and/or the presence of hepatic encephalopathy
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administrative data to study the epidemiology and out-
comes of AH should be scrutinized. In one study, Sandahl
and colleagues used this ICD-10 code to identify AH cases
from the Danish National Registry of Patients and describe
its incidence and associated mortality [8]. In total, 1,951
suspected cases of AH were identified between 1999 and
2008. The annual incidence increased from 37 to 46 per
million population in men and from 24 to 34 per million
in women. However, according to our results, close to half
of the patients identified in this study may not have been
true cases of AH. This study also reported 84-day mortal-
ity ranging from 14 % to 24 %, similar to the 90-day mor-
tality rate of 17 % for confirmed AH in our study. In
another study, Liangpunsakul used the Nationwide
Inpatient Sample hospitalization database to report the
outcomes of patients hospitalized for AH in the United
States with case identification using the ICD-9 code for
this condition (571.1) [9]. The study showed that AH rep-
resented 0.71 % of all hospital admissions in 2007 and
reported an in-hospital mortality rate of 6.8 %. Although
our study validated only the ICD-10 coding classification
(as ICD-9 codes were unavailable), there is no clear ration-
ale for the accuracy to differ among the two classification
systems both of which include a single code for AH.
Moreover, a study by Quan and colleagues that used the
DAD (as in our study) demonstrated that the coding ac-
curacies between the ICD-9 and ICD-10 classifications for
liver diseases are very similar (AH was not examined spe-
cifically in this study) [37]. Therefore, our results should
be generalizable to databases using either the ICD-9 or
ICD-10 classifications.
The diagnosis field in which the code for AH was re-
corded in the administrative database (i.e. primary vs.
secondary) had a significant impact on algorithm valid-
ity. Indeed, the majority (89 %) of confirmed AH cases
had the AH code recorded as the primary diagnosis (vs.
50 % among non-AH hospitalizations). Accordingly, the
PPV improved from 54 % to 67 % when the cohort was
restricted to those with AH as the primary diagnosis
compared with one of the secondary diagnosis fields. Pa-
tients with a severe presentation were also more likely to
have AH recorded as the primary diagnosis. Specifically,
77 % of cases with hepatic encephalopathy and/or a
Maddrey DF ≥32 had AH as a primary diagnosis com-
pared with only 59 % of those with mild hepatic dys-
function. Algorithms that also included diagnosis codes
for ascites or gastrointestinal hemorrhage had improved
performance, particularly when restricted to cases with a
primary diagnosis of AH in which PPVs of 76 % to 78 %
were observed. The corollary is that studies focused on
patients with severe AH may potentially identify these
cases from administrative databases by restricting to
cases with AH as the primary diagnosis plus these
Table 2 Prevalence and performance characteristics of algorithms including an alcoholic hepatitis code and codes for associated
conditions








Diagnosis (n = 161)
AH as Secondary





Ascites 27 % (61) 38 % (46) 75 % (63–86) 78 % (65–89) 6 % (26–88) 83 % (70–93) 46 % (19–75)
GI hemmorrhage 34 % (77) 39 % (48) 62 % (51–73) 76 % (62–87) 30 % (13–53) 80 % (66–90) 30 % (14–50)
Hepatic encephalopathy 2.6 % (6) 2.5 % (3) 50 % (12–88) 100 % (16–100) 25 % (1–81) 50 % (12–88) —
Cirrhosis 25 % (58) 29 % (35) 60 % (47–73) 70 % (53–83) 39 % (17–64) 69 % (53–82) 31 % (9–61)
Alcoholic hepatic failure 4.8 % (11) 8.2 % (10) 91 % (59–100) 89 % (52–100) 44 % (20–70) 90 % (55–100) 33 % (10–65)
Malnutrition 3.0 % (7) 4.1 % (5) 71 % (29–96) 60 % (15–95) 100 % (16–100) 80 % (28–99) 50 % (1–99)
HRS/ Renal failure 16 % (36) 18 % (22) 61 % (43–77) 67 % (46–83) 44 % (14–79) 68 % (48–84) 38 % (9–76)
Pancreatitis 7.9 % (18) 4.9 % (6) 33 % (13–59) 63 % (24–91) 10 % (0–45) 86 % (42–100) 0 % (0–28)
Alcohol abuse 35 % (81) 38 % (46) 57 % (43–68) 68 % (54–79) 27 % (11–50) 70 % (56–82) 32 % (16–52)
Alcohol dependence 26 % (60) 28 % (34) 57 % (43–69) 74 % (60–86) 17 % (4–41) 76 % (59–88) 26 % (10–48)
Alcohol withdrawal 21 % (47) 16 % (19) 40 % (26–56) 62 % (41–80) 14 % (3–36) 62 % (41–80) 14 % (3–36)
GI gastrointestinal, HRS hepatorenal syndrome
Table 3 Performance characteristics for algorithms for alcoholic
hepatitis according to the number of associated conditions a
Number of
conditions a
Prevalence % (n) Positive predictive
value (PPV) %
(95 % CI)
Overall (n= 228) Confirmed AH (n= 122)
0 11 % (24) 7.4 % (9) 38 % (19–59)
≥1 89 % (204) 93 % (113) 55 % (48–62)
≥2 61 % (139) 65 % (79) 57 % (48–65)
≥3 30 % (68) 34 % (42) 62 % (49–73)
≥4 13 % (29) 19 % (23) 79 % (60–92)
≥5 4 % (9) 5.7 % (7) 78 % (40–97)
a Associated conditions as shown in Table 2. Prevalent cases represent those
with an AH diagnosis code plus codes for the associated conditions
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associated conditions. However, the prevalence of these
cirrhosis-related complications was low enough (<40 %)
in confirmed AH cases that any study employing this
methodology will have reduced sensitivity for the identi-
fication of all relevant cases. Based on the sub-optimal
accuracy observed in our study, we would advise that
any AH case identified in this manner be confirmed via
a review of medical records.
In addition to examining the impacts of coding details
and disease severity on the validity of an AH code in the
administrative data, we studied the effects of year and
hospital of admission. Despite the presence of different
health records coders at the three hospitals in our region,
coding validity was similar supporting the generalizability
of our findings. Moreover, the PPV of an AH code did not
differ across study years, potentially supporting the tem-
poral trends in disease incidence suggested by the study of
Sandahl and colleagues [8]. In this regard, we did not ob-
serve an increase in the number of admissions over time
although the sample size of our study was limited.
While previous studies have confirmed the validity of
administrative data for the identification of patients with
various liver disorders [19, 38, 39], our results suggest
that caution is needed when using these data sources to
study AH. However, the major challenge with our ana-
lysis relates to the diagnostic definition for AH. Specific-
ally, AH represents a spectrum ranging from mild
abnormalities in liver biochemistry to life-threatening
liver failure due to abusive alcohol consumption when
other causes of liver disease (e.g. viral hepatitis and drug
hepatotoxicity) have been excluded. Although AH has
characteristic histological findings including steatosis,
ballooned hepatocytes, Mallory bodies, lobular neutro-
philc inflammation, and centrizonal fibrosis [40], liver
biopsy is not routinely performed in our region, nor are
these findings specific (e.g. they may be seen in patients
with non-alcoholic steatohepatitis). The diagnostic criteria
suggested by Lucey et al. (i.e. elevated AST but <300 IU/L,
AST to ALT ratio >2, serum bilirubin >86 μmol/L, elevated
INR, and neutrophilia in patients with ascites and a history
of heavy alcohol use) [1] are very stringent and would
mostly capture only patients with severe AH. In light of
this fact, we utilized a less rigorous definition of AH that
allowed us to identify a wider spectrum of suspected AH
cases. Moreover, since AST is not part of standard liver
biochemical profiles in our region and due to the high cor-
relation between AST and ALT, we considered ALT in
place of AST when necessary. Nevertheless, since such a
biochemically focused, even more lenient, case definition is
generally not strictly followed in clinical practice, patients
who do not meet all of these criteria may still be diagnosed
with AH by their physician thereby contributing to the
sub-optimal accuracy of the diagnosis code observed in
our study.
Among the 106 patients who did not fulfill our diag-
nostic criteria for confirmed AH, 31 patients clearly did
not have AH upon medical records review. The diagno-
sis for these patients includes cirrhosis, sepsis, recent
history of AH, pancreatitis, acetaminophen toxicity, co-
caine use, heart failure and alcohol intoxication.
Taking into consideration that our definition of AH
may not be strictly followed by physicians, we performed
a sensitivity analysis using a loosened definition of AH
that confirmed diagnosis of AH if patients fulfilled
both of the following criteria: heavy alcohol con-
sumption (>196 g/week or >56 g in any day among
males, and >98 g/week or >42 g in any day among fe-
males) and exclusion of other causes of acute hepatic
dysfunction (e.g. drug hepatotoxicity, autoimmune hepa-
titis, ischemic hepatitis, etc.). With this loosened diagnos-
tic criteria, PPV improved to 73 % (95 % CI 67-79 %), up
from 54 %. This improved PPV remains sub-optimal,
thus further supporting our initial findings that AH was
not accurately and completely coded in the administra-
tive data. Realizing the limitations of both sets of diag-
nostic criteria, one could infer that the true PPV for the
AH diagnosis code lies within 54 % to 73 %.
Our study has several limitations that warrant discus-
sion. First, we lack data for a control group representa-
tive of the general hospitalized population. Without
controls, the sensitivity, specificity and NPVs of the diag-
nosis code for AH (and related algorithms) cannot be
calculated. Second, since this is a retrospective study,
the reliability of patients’ self-reported alcohol intake is
questionable. On numerous occasions, multiple descrip-
tions of alcohol consumption were recorded in the med-
ical record. Anecdotally, patients tended to admit to
greater alcohol intake when questioned by addictions spe-
cialists. As a result, we utilized a hierarchical approach to
record alcohol consumption (see Methods). Since the
amount of alcohol intake is a vital criterion in the refer-
ence standard for an AH diagnosis, underreporting may
have led to an underestimation of AH in our study.
Conclusions
In conclusion, the validity of ICD-10 coding for AH in this
Canadian hospitalization database appears sub-optimal.
Although the accuracy of coding algorithms improved
when restricted to patients with AH in the primary diag-
nosis field or with codes indicative of hepatic complica-
tions (e.g. ascites and gastrointestinal haemorrhage), the
use of administrative data in epidemiologic studies of AH
should be undertaken cautiously. If administrative data is
used for case identification, confirmation of the diagnosis
via medical record review is recommended.
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Information; GI: Gastrointestinal; HE: Hepatic encephalopathy; ICD: International
statistical classification of disease; INR: International normalized ratio;
IQR: Interquartile range; NIS: Nationwide Inpatient Sample; PPV: Positive
predictive value.
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